Zacks upgraded shares of Gilead Sciences (NASDAQ:GILD) from a neutral rating to an outperform rating in a report issued on Friday. They currently have $99.00 target price on the stock. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 0.17%. On last trading day company shares ended up $80.94. Analysts mean target price for the company is $100.26. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 7.94%.
Delta Air Lines, Inc. (NYSE:DAL) recently announced its plan for a 50% increase in its dividend per share and a $2 billion share repurchase program to be completed by December 2016. Delta Air Lines, Inc. (NYSE:DAL) shares advanced 1.37% in last trading session and ended the day on $39.16. DAL gross Margin is 34.50% and its return on assets is 21.90%.Delta Air Lines, Inc. (NYSE:DAL) quarterly performance is 20.86%.
Despite underwhelming sales of its previous games consoles in Japan, Microsoft Corporation (NASDAQ:MSFT) has remained true to its promise of bringing Xbox One to the Land of the Rising Sun, and has announced an official release date and price point. Microsoft Corporation (NASDAQ:MSFT) shares moved up 0.05% in last trading session and was closed at $40.12, while trading in range of $40.00 – $40.37. Microsoft Corporation (NASDAQ:MSFT) year to date (YTD) performance is 8.81%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)on 15 may recorded first quarter revenues of $2.9 million benefiting from revenues recorded for its obesity drug, Belviq. However, revenues were way below the Zacks Consensus Estimate of $8 million. The company did not recognize any revenues in the first quarter of 2013. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended the last trading day at $6.19. Company weekly volatility is calculated as 4.03% and price to cash ratio as 5.30.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a negative weekly performance of -3.73%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced on 20 may the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. On last trading day company shares ended up $37.42.